Intrinsic Value of S&P & Nasdaq Contact Us

Nuwellis, Inc. NUWE NASDAQ

NASDAQ Capital Marke • Healthcare • Medical - Devices • US • USD

SharesGrow Score
40/100
1/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Nuwellis, Inc. (NUWE) — Analyst outlook / Analyst consensus target is. Based on 2 analyst ratings, the consensus is bullish — 1 Buy, 1 Hold.

Analysts estimate Earnings Per Share (EPS) of $-983.01 and revenue of $0.01B for the next fiscal year.

Earnings Per Share (EPS) track record: 2024: actual $-8.00 vs est $-983.01 (beat +99.2%). 2025: actual $-25.39 vs est $-25.72 (beat +1.3%). Analyst accuracy: 0%.

NUWE Analyst Ratings

Buy
2
Ratings
1 Buy
1 Hold
Based on 2 analysts giving stock ratings to Nuwellis, Inc. in the past 3 months
Rating breakdown
Buy
1 50%
Hold
1 50%
50%
Buy
1 analysts
50%
Hold
1 analysts
0%
Sell
0 analysts

EPS Estimates — NUWE

0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024 Actual –$8.00 vs Est –$983.01 ▲ 12,180.7% off
2025 Actual –$25.39 vs Est –$25.72 ▲ 1.3% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.

Revenue Estimates — NUWE

99%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024 Actual $0.009B vs Est $0.009B ▼ 1.6% off
2025 Actual $0.008B vs Est $0.008B ▲ 1.4% off
Revenue Trend
Revenue has declined over the period shown. Analysts expect stable revenue going forward.
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message